Advanced Search

 

Study ID Status Title Patient Level Data
S3A40182 Completed A Stratified, Randomized, Double-Blind Comparison of Intravenous Ondansetron Administered as a Multiple Dose Regimen Versus Two Single Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting
S3A40206 Completed A double-blind, placebo-controlled multicentre study of intravenous ondansetron in the prevention of post-operative emesis (retching and vomiting) in paediatric patients undergoing strabismus surgery
S3A40231 Completed A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery
S3A40232 Completed An Open-Label Study of IV Ondansetron Plus Dexamethasone for the Prevention of Emesis Associated with Different Degrees of Emetogenic Chemotherapy
S3A40240 Completed A randomised, double-blind, parallel group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
S3A40241 Completed A Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Safety of Ondansetron plus Dexamethasone, Ondansetron and Tropisetron in the Control of Acute Cisplatin-induced Nausea and Emesis
S3A40262 Completed A randomized, double-blind, placebo-controlled, multi-center study of intravenous ondansetron for the prevention of postoperative emesis in pediatric patients undergoing outpatient surgery.
S3A40275 Completed A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery.
S3A40284 Completed A randomised double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of a single intravenous dose of Ondansetron in the prevention of post-operative nausea and emesis in paediatric patients having general anaesthesia and undergoing surgery for tonsillectomy with o ...
S3A40317 Completed A randomised, double-blind, placebo-controlled multicentre parallel-group study to compare the efficacy and safety of a single intravenous bolus dose of ondansetron, metoclopramide and placebo in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergo ...
S3A40318 Completed A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of single doses of orally administered ondansetron in the prevention of post-operative nausea and vomiting in patients having general anaesthesia and undergoing major gynaecological surgery
S3A40319 Completed A Phase IV, Multi-Center, Two-Arm, Single-Dose Pharmacokinetic Study of Intravenous ZOFRAN in Pediatric Surgical Patients from 1 Month to 24 Months of Age
S3A40320 Completed An Open-label, Multicenter, Study of the Safety and Antiemetic Effect of 0.15 mg/kg Intravenous Ondansetron Hydrochloride Administered for Three Doses to Pediatric Cancer Patients Aged 6 Months to 48 Months Who Are Receiving Moderately to Highly Emetogenic Chemotherapy
S3A40323 Completed A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Intravenous Ondansetron Hydrochloride 0.1 mg/kg for the Prevention of Postoperative Emesis in Pediatric Surgical Subjects Ages 1 Month to 24 Months Who Are Undergoing Routine Surgery Under General Anesthesia.
S3AA1002 Completed A Bioequivalence Study Comparing Three 8-mg Zofran® Tablets to a Single 24-mg Ondansetron Tablet
S3AA1003 Completed Dose-Response Effects of Ondansetron vs. Placebo on Morphine-Induced Nausea, Gastric Dysrhythmias and Plasma Vasopressin
S3AA3004 Completed A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated With Moderately-High Emetogenic Chemotherapy
S3AA3012 Completed A Randomized, Double-Blind Study of Oral Ondansetron, 8mg Twice Daily, 24mg Once Daily and 32mg Once Daily, in the Prevention of Nausea and Vomiting Associated With Cisplatin Chemotherapy
S3AA3013 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Single Dose Ondansetron 8mg and Single Dose Ondansetron 16mg for the Treatment of Opioid-Induced Nausea and Emesis in Subjects Experiencing Acute Pain
S3AA4001 Completed A Multicenter Study to Evaluate the Efficacy and Safety of a Repeat Dose of Ondansetron in Ambulatory Surgery Patients who do not Achieve Adequate Control of Postoperative Nausea and Vomiting Following Prophylaxis With Open-Label Intravenous Ondansetron
S3AA4002 Completed A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin Chemotherapy
S3AA4003 Completed A Stratified, Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Moderately-Emetogenic Chemotherapy
S3AB3003 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Compare the Efficacy and Safety of Intravenous Doses of Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis in Patients Undergoing Elective Major Abdominal Surgery
S3AB3004 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Intravenous Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis In-Patients Undergoing Major Gynaecological Surgery
S3AB3005 Completed A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron 8mg bd Tablet and Ondansetron ZYDIS™ 8mg bd in the Control of Emesis and Nausea Induced by Cyclophosphamide-Containing Chemotherapy Treatment in Cancer Patients

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.